

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/765,382	01/27/2004	Ernest J. St. Pierre	BSCU-032/02US	2525
22903	7590 08/01/2006		EXAMINER	
COOLEY GODWARD LLP			SNOW, BRUCE EDWARD	
ATTN: PATE THE BOWEN			ART UNIT	PAPER NUMBER
875 15TH STREET, N.W. SUITE 800			3738	
WASHINGTO	ON, DC 20005-2221			

DATE MAILED: 08/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Commence	10/765,382	ST. PIERRE, ERNEST J.
Office Action Summary	Examiner	Art Unit
	Bruce E. Snow	3738
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  16(a). In no event, however, may a reply be tin  rill apply and will expire SIX (6) MONTHS from  cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 15 Ma     This action is FINAL. 2b) ☐ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 10-32 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 10-32 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers  9) ☐ The specification is objected to by the Examine. 10) ☐ The drawing(s) filed on is/are: a) ☐ acceedable. Applicant may not request that any objection to the orange of the correction of the orange of the correction. The oath or declaration is objected to by the Examine.	vn from consideration.  r election requirement.  r.  epted or b) □ objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati ity documents have been receive ı (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	

### **DETAILED ACTION**

Applicant's arguments and amendments filed 5/15/06 overcame all previous art rejections but are most in view of the new ground(s) of rejection.

Applicant's submission of a terminal disclaimer is noted and has been forwarded to the appropriate personnel for review.

# **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 10-26 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 6,620,202. Although the conflicting claims are not identical, they are not patentably distinct from each other claiming the identical stent, for example, current claim 1 corresponds to claim 1 comprising a first section having a first durometer, second section having a

greater second durometer, and a third section comprised of material from both the first and second material.

Claims 10-26 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 6,719,804. Although the conflicting claims are not identical, they are not patentably distinct from each other claiming the identical stent, for example, current claim 1 corresponds to claim 18 comprising a first section having a first durometer, second section having a greater second durometer, and a third section comprised of material from both the first and second material.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 10 and 12-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldberg et al (4,874,360) in view of Wang (6,135,992).

Goldberg et al discloses a medical device comprising:

a first section 12 including a retention structure comprising a first material having a first durometer value;

a second section 11 including a second retention structure comprising a second material having a second durometer value higher than the first (see column 2, lines 53-60);

and a third section location between said first and second sections shown in figure 6. However, Goldberg fails to teach the third section comprises a co-extrusion of the first and second materials forming the third section.

Wang teaches a similar device for use in various body lumens comprising a first section comprising a first material having a first durometer value and a second section comprising a second material having a second durometer value higher than the first and further teaches a third section, i.e. 19, which is a co-extrusion of the first and second materials.

It would have been obvious to one having ordinary skill in the art to have utilized the teaching of Wang to form the medial device of Goldberg having a co-extruded third section of the first and second materials which are distinct and associated in an irregular configuration because:

"this type of differential stiffness catheter is usually made by hand by joining two or more pieces of tubing together, they are labor intensive and therefore expensive to manufacture. Moreover, these catheters tend to buckle and to kink at the joints where there occurs an abrupt change in stiffness. Buckling and kinking are very undesirable characteristics for catheters. Also, there is a tendency for the joints to separate leaving the tip of the catheter inside the body and requiring surgery to retrieve it." See 1:60 et seq. of Wang.

And, the "co-extruded, e.g., "wedged into" one another to produce an extremely secure, practically non-breakable joint between the two materials. The merging of the two materials is very smooth and gradual to eliminate the buckling and kinking that usually occurs at abrupt joints between two materials of different stiffness." See 3:12 et seq. of Wang.

Regarding claim 21, higher durometer produces a higher retention strength and vise versa.

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Goldberg et al (4,874,360) in view of Wang (6,135,992).

Goldberg et al and Wang teaches the medical stent as described above, however, are silent regarding ethylene vinyl acetate. Said material is well known in the art for stents and it would have been obvious to one having ordinary skill in the art to have utilized it for the stent of Goldberg et al for its know characteristics including biocompatibility.

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruce E. Snow whose telephone number is (571) 272-4759. The examiner can normally be reached on Mon-Thurs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

bes

BRUCE SNOW PRIMARY EXAMINER